tiprankstipranks
Argent Biopharma (RGTLF)
OTHER OTC:RGTLF
US Market
RGTLF
Argent Biopharma
RESEARCH TOOLSreports

Argent Biopharma (RGTLF) Ratios

31 Followers

Argent Biopharma Ratios

RGTLF's free cash flow for Q4 2024 was AU$-0.71. For the 2024 fiscal year, RGTLF's free cash flow was decreased by AU$ and operating cash flow was AU$-32.12. See a summary of the company’s cash flow.
Ratios
TTM
Jun 24Jun 23Jun 22Jun 21
Liquidity Ratios
Current Ratio
 0.19 0.19 0.23 0.18
Quick Ratio
 0.18 0.18 0.15 0.09
Cash Ratio
 0.09 0.09 0.06 0.02
Solvency Ratio
 -1.54 -1.54 -0.98 -1.11
Operating Cash Flow Ratio
 0.00 0.00 0.00 0.00
Short-Term Operating Cash Flow Coverage
 0.00 0.00 0.00 0.00
Net Current Asset Value
AU$ -9.07MAU$ -9.07MAU$ -13.87MAU$ -15.59M
Leverage Ratios
Debt-to-Assets Ratio
 3.36 3.36 0.10 0.06
Debt-to-Equity Ratio
 -0.96 -0.96 -0.20 -0.08
Debt-to-Capital Ratio
 -24.18 -24.18 -0.25 -0.08
Long-Term Debt-to-Capital Ratio
 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 -0.29 -0.29 -2.09 -1.32
Debt Service Coverage Ratio
 -2.13 -2.13 -32.69 -59.48
Interest Coverage Ratio
 -301.01 -301.01 -37.85 -46.28
Debt to Market Cap
 2.61 0.00 0.00 0.00
Interest Debt Per Share
 0.00 0.00 0.04 0.31
Net Debt to EBITDA
 -0.43 -0.43 -0.02 -0.02
Profitability Margins
Gross Profit Margin
76.50%76.50%22.86%42.82%
EBIT Margin
-3049.63%-3049.63%-1915.19%-613.85%
EBITDA Margin
-2914.38%-2914.38%-1770.00%-591.65%
Operating Profit Margin
-2646.84%-2646.84%-2049.40%-460.46%
Pretax Profit Margin
-3058.43%-3058.43%-1969.34%-623.80%
Net Profit Margin
-3058.43%-3058.43%-1967.34%-614.71%
Continuous Operations Profit Margin
-3058.43%-3058.43%-1969.34%-623.86%
Net Income Per EBT
100.00%100.00%99.90%98.54%
EBT Per EBIT
115.55%115.55%96.09%135.47%
Return on Assets (ROA)
-723.12%-723.12%-162.51%-210.75%
Return on Equity (ROE)
258.94%206.77%340.24%277.42%
Return on Capital Employed (ROCE)
184.66%184.66%1315.01%461.79%
Return on Invested Capital (ROIC)
4766.67%4766.67%1567.67%489.40%
Return on Tangible Assets
-723.12%-723.12%-162.51%-210.75%
Earnings Yield
0.00%0.00%-139.31%-1726.83%
Efficiency Ratios
Receivables Turnover
 1.55 1.55 1.87 6.38
Payables Turnover
 0.08 0.08 0.72 0.89
Inventory Turnover
 1.03 1.03 0.79 1.54
Fixed Asset Turnover
 1.33 1.33 0.13 0.45
Asset Turnover
 0.24 0.24 0.08 0.34
Working Capital Turnover Ratio
 -0.06 -0.06 -0.09 -0.57
Cash Conversion Cycle
 -4.24K -4.24K 151.82 -117.28
Days of Sales Outstanding
 235.00 235.00 195.19 57.25
Days of Inventory Outstanding
 353.15 353.15 464.69 237.35
Days of Payables Outstanding
 4.83K 4.83K 508.06 411.88
Operating Cycle
 588.15 588.15 659.88 294.60
Cash Flow Ratios
Operating Cash Flow Per Share
 0.00 0.00 0.00 0.00
Free Cash Flow Per Share
 0.00 0.00 -0.39 -3.83
CapEx Per Share
 0.00 0.00 <0.01 0.25
Free Cash Flow to Operating Cash Flow
 0.00 0.00 0.00 0.00
Dividend Paid and CapEx Coverage Ratio
 0.00 0.00 0.00 0.00
Capital Expenditure Coverage Ratio
 0.00 0.00 0.00 0.00
Operating Cash Flow Coverage Ratio
 0.00 0.00 0.00 0.00
Operating Cash Flow to Sales Ratio
 0.00 0.00 0.00 0.00
Free Cash Flow Yield
-306.08%0.00%-114.44%-933.72%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 0.00 0.00 -0.72 -0.06
Price-to-Sales (P/S) Ratio
 5.20 0.00 14.12 0.36
Price-to-Book (P/B) Ratio
 0.00 0.00 -2.44 -0.16
Price-to-Free Cash Flow (P/FCF) Ratio
 -0.33 0.00 -0.87 -0.11
Price-to-Operating Cash Flow Ratio
 0.00 0.00 0.00 0.00
Price-to-Earnings Growth (PEG) Ratio
 0.00 0.00 <0.01 >-0.01
Price-to-Fair Value
 0.00 0.00 -2.44 -0.16
Enterprise Value Multiple
 -0.61 -0.43 -0.82 -0.08
Enterprise Value
 10.30M 7.26M 12.93M 1.54M
EV to EBITDA
 -0.61 -0.43 -0.82 -0.08
EV to Sales
 17.65 12.45 14.51 0.45
EV to Free Cash Flow
 -1.11 -0.78 -0.90 -0.14
EV to Operating Cash Flow
 0.00 0.00 0.00 0.00
Tangible Book Value Per Share
 0.00 0.00 -0.16 -2.77
Shareholders’ Equity Per Share
 0.00 0.00 -0.14 -2.55
Tax and Other Ratios
Effective Tax Rate
 0.00 0.00 0.00 >-0.01
Revenue Per Share
 0.00 0.00 0.02 1.15
Net Income Per Share
 0.00 0.00 -0.47 -7.08
Tax Burden
 1.00 1.00 1.00 0.99
Interest Burden
 1.00 1.00 1.03 1.02
Research & Development to Revenue
 6.16 6.16 2.61 0.59
SG&A to Revenue
 13.81 13.81 9.73 3.58
Stock-Based Compensation to Revenue
 0.00 0.00 0.00 0.00
Income Quality
 0.00 0.00 0.00 0.00
Currency in AUD